Coagulopathy, marantic endocarditis, and cerebrovascular accidents as paraneoplastic features in medullary thyroid cancer - Case report and review of the literature

Thyroid

Volumn 13, Issue 6, 2003, Pages 601-605

  Lal, Geeta ^a   Brennan, Todd V ^a   Hambleton, Julie ^b   Clark, Orlo H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; CASE REPORT; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENDOCARDITIS; HUMAN; HUMAN TISSUE; HYPERCOAGULABILITY; LUNG METASTASIS; LYMPHADENECTOMY; MALE; MEDICAL LITERATURE; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; THROMBOEMBOLISM; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0037493022     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072503322238872     Document Type: Article

References (33)

1. Kebebew E, Clark OH 2000 Medullary thyroid cancer. Curr Treat Options Oncol 1:359-367.
2. Trousseau A 1865 Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel-Dieu de Paris, Vol 3, 2nd ed. Balliere, Paris, p 654.
3. Frenkel EP, Bick R 1998 Issues of thrombosis and hemorrhagic events in patients with cancer. In Vivo 12:625-628.
4. Falanga A, Rickles FR 1999 Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173-182.
5. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A 1996 Upper extremity deep vein thrombosis in cancer patients with venous access devices - Prophylaxis with a low-molecular-weight heparin (Fragmin). Thromb Haemost 75:251-253.
6. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S 1988 The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404-407.
7. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P 1994 Double blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889.
8. Barbui T, Finazzi G, Grassi A, Marchioli M 1996 Thrombosis in cancer patients treated with haematopoietic growth factors - A meta-analysis. Thromb Haemost 75:251-253.
9. Rickles FR, Levine MN, Edwards RL 1992 Hemostatic alterations in cancer patients. Cancer Metastasis Rev 11:237-248.
10. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW 1993 Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133.
11. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL 1998 The risk of the diagnosis of cancer after primary deep vein thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173.
12. Raveh E, Cohen M, Shpitzer T, Feinmesser R 1995 Carcinoma of the thyroid: A cause for hypercoagulability? Ear Nose Throat J 74:110-112.
13. Tiede DJ, Tefferi A, Kochhar R, Thompson GB, Hay ID 1994 Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking. Cancer 73:702-705.
14. Glass JP 1993 The diagnosis and treatment of stroke in a patient with cancer: nonbacterial thrombotic endocarditis (NBTE): A case report and review. Clin Neurol Neurosurg 95:315-318.
15. Lee AYY, Levine MN 2000 Management of venous thromboembolism in cancer patients. Oncology 14:409-417.
16. Bick RI, Strauss JF, Frenkel EP 1996 Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 10:875-907.
17. Kleinschmidt K, Charles R 2001 Pharmacology of low molecular weight heparins. Emerg Med Clin North Am 19:1025-1049.
18. Lebeau B, Chastang C, Brechot J-M, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E 1994 Subcutaneous heparin treatment increases survival in small-cell lung cancer. Cancer 74:3845.
19. Norrby K 1993 Heparin and angiogenesis: A low-molecular weight fraction stimulates angiogenesis systemically. Haemostasis 23(Suppl 1):141-149.
20. Sack GH Jr, Levin J, Bell WR 1977 Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms:clinical, pathophysiologic and therapeutic features. Medicine 56:1-37.
21. Berber E, Flesher N, Siperstein AE 2002 Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985-990.
22. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T 1996 Medullary thyroid cancer: Analysis of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305-310.
23. Chi DD, Moley JF 1998 Medullary thyroid carcinoma: Genetic advances, treatment recommendation and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin North Am 7:681-706.
24. Droz JP, Schlumberger M, Rougier P, Ghosh M, Gardet P, Parmentier C 1990 Chemotherapy in metastatic non-anaplastic thyroid cancer: Experience at the Institut Gustave-Roussy. Tumori 76:480-483.
25. Petursson SR 1988 Metastatic medullary thyroid carcinoma: Complete response to combination chemotherapy with dacarbazine and 5-fluoro-uracil. Cancer 62:1899-1903.
26. Orlanci F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A 1994 Chemotherapy with dacarbazine and 5-fluro-uracil in advanced medullary thyroid cancer. Ann Oncol 5:763-765.
27. Wu LT, Auerbach SD, Ball DW, DeBustros A, Baylin SB, MacGuire WP III 1994 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. Cancer 73:432-436.
28. Frame J, Kelson D, Kemeny N, Cheng E, Niedzwiecki D, Heelan R, Lipperman RA 1988 A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol 11:490-495.
29. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
30. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD 2001 STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054-5058.
31. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480.
32. Krystal GW, Honsawek S, Litz J, Buchdunger E 2000 The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326.
33. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R 1999 Radiolabeled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10(Suppl 2):S23-S29.